COMMUNIQUÉS West-GlobeNewswire

Sai Life Sciences augments DMPK capabilities to ace large-scale collaborations
01/02/2024
HYDERABAD, India, Feb. 01, 2024 (GLOBE NEWSWIRE) -- To offer global big pharma clients cutting-edge, end-to-end drug metabolism and pharmacokinetics (DMPK) services, Sai Life Sciences, a global Contract Research, [...]
HUTCHMED to Announce 2023 Final Results
01/02/2024
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Feb. 01, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM: HCM; SEHK:13) will be announcing its final results for the year ended December [...]
EnteroBiotix Strengthens its Executive Team, Appoints COO and CFO
01/02/2024
GLASGOW, Scotland, Feb. 01, 2024 (GLOBE NEWSWIRE) -- EnteroBiotix Limited (“EBX”), a clinical stage biopharmaceutical company with the premier platform for full-spectrum microbiome therapeutics, today announced the [...]
Launch of GIO Therapeutics, founded by Cumulus Oncology, to develop therapeutics targeting G protein-coupled receptors to treat cancer and inflammation
01/02/2024
Launch of GIO Therapeutics, founded by Cumulus Oncology, to develop therapeutics targeting G protein-coupled receptors to treat cancer and inflammation Newly appointed CEO, Dr Xavier Leroy, will lead GIO Therapeutics in [...]
Legacy Novozymes delivers solid last full-year results
01/02/2024
Legacy Novozymes is delivering solid growth and earnings in a year characterized by changing market demands, with 6% organic sales growth in Q4 and 5% organic sales growth in 2023. This marks the last financial [...]
Genflow Biosciences Releases 2023 Year-End Review and Highlights Key Priorities for 2024
01/02/2024
Genflow Biosciences Plc ("Genflow" or "the Company") LONDON, Feb. 01, 2024 (GLOBE NEWSWIRE) -- The Company (LSE:GENF) (OTCQB:GENFF), an emerging leader in the field of longevity research developing therapeutics that [...]
Michael Austwick Joins Verona Pharma as Non-Executive Director
01/02/2024
LONDON and RALEIGH, N.C., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”) announces Mr. Michael Austwick has today joined the board as a Non-Executive Director. Mr. Austwick brings a [...]
Results update for 2023 – unaudited
01/02/2024
6% organic sales growth in Q4 and 5% for the full year with solid margins and free cash flow generation As Novozymes just closed the combination with Chr. Hansen on January 29, and the annual report now is expected to [...]
Press Release: François-Xavier Roger appointed Chief Financial Officer, member of Sanofi Executive Committee
01/02/2024
François-Xavier Roger appointed Chief Financial Officer, member of Sanofi Executive Committee Paris, February 1, 2024 . François-Xavier Roger will be appointed Chief Financial Officer and a member of Sanofi’s Executive [...]
Communiqué de presse : François-Xavier Roger nommé Directeur Financier, membre du Comité exécutif de Sanofi
01/02/2024
François-Xavier Roger nommé Directeur Financier, membre du Comité exécutif de Sanofi Paris, 1er février, 2024 . François-Xavier Roger sera nommé Directeur Financier et membre du Comité Exécutif de Sanofi à compter du [...]
Press Release: Sanofi Delivers Solid Sales and Business EPS Growth at CER Amidst Successful Product Launches and Advancements in Immunology Pipeline
01/02/2024
Sanofi Delivers Solid Sales and Business EPS Growth at CER Amidst Successful Product Launches and Advancements in Immunology Pipeline Paris, February 1, 2024 Q4 2023 sales growth of 9.3% at CER and business EPS (1) [...]
Communique de presse - 2023 : Croissance des ventes et du bénéfice net par action à TCC, succès des lancements de produits et avancée du portefeuille R&D en Immunologie
01/02/2024
2023 : Croissance des ventes et du bénéfice net par action à TCC, succès des lancements de produits et avancée du portefeuille R&D en Immunologie Paris, le 1 février 2024 T4 2023 : Augmentation des ventes de 9,3% à [...]
Sandoz announces changes in the Board of Directors
01/02/2024
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Graeme Pitkethly nominated as candidate for election to the Sandoz Board of Directors at the upcoming Annual General Meeting [...]
New long-term data for Roche’s Vabysmo show sustained retinal drying and vision improvements in retinal vein occlusion (RVO)
01/02/2024
Vabysmo sustained robust drying of retinal fluid, often associated with distorted or blurry vision Up to 60% of people receiving Vabysmo were able to extend treatment intervals to three or four months apart Detailed [...]
[Ad hoc announcement pursuant to Art. 53 LR] Roche exceeds guidance and achieves sales growth of 1% (CER) for 2023 despite sharp COVID-19 sales decline
01/02/2024
Group sales grow by 1% 1 at constant exchange rates (CER; -7% in CHF), more than offsetting the decline in COVID-19-related sales and biosimilar erosion, and thereby exceeding 2023 guidance Excluding COVID-19 products, [...]
[Annonce événementielle au sens de l’art. 53 RC] Roche dépasse les projections et affiche une croissance des ventes de 1 % (TCC) en 2023, malgré un net recul des ventes lié au COVID-19
01/02/2024
Le chiffre d’affaires consolidé progresse de 1 % 1 à taux de change constants (TCC ; -7 % en CHF), faisant plus que contrebalancer le recul des ventes lié au COVID-19 et l’érosion induite par les biosimilaires, et [...]
Revive Therapeutics Ltd. Announces Closing of the First Tranche of Its Private Placement for Gross Proceeds of $913,500
31/01/2024
NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES AND DOES NOT CONSTITUTE AN OFFER OF THE SECURITIES DESCRIBED HEREIN TORONTO, Jan. 31, 2024 (GLOBE NEWSWIRE) -- REVIVE THERAPEUTICS [...]
Tarsus to Participate in Fireside Chat at the Sixth Annual Guggenheim Healthcare Talks Conference
31/01/2024
IRVINE, Calif., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients [...]
Intellia Therapeutics Announces Publication of Positive Interim Phase 1 Data for NTLA-2002 in Patients with Hereditary Angioedema in the New England Journal of Medicine
31/01/2024
Data reinforce the potential of NTLA-2002 to eliminate angioedema attacks in people living with hereditary angioedema (HAE) after a single dose A single dose of NTLA-2002 led to 95% mean reduction in monthly HAE attack [...]

Pages